Co-founder, CEO and President of Philogen. He graduated in Business Administration and Economics at the Bocconi University in Milan, specializing in Corporate Finance. Expertise in Financial Consulting, Tax and Audit Advisor and Business Administrator. Partner of the "Studio Neri - Tanini". Formerly in the Board of the University of Siena as a representative of the Italian Government, formerly auditor of the Cassa di Risparmio di San Miniato (CRSM) S.p.A., MPS Banca Verde S.p.A., MPS Fiduciaria S.p.A., MPS Professional S.p.A., and of several firms.
Co-founder and Director of IP & Licensing at Philogen S.p.A. Giovanni Neri graduated in Biology at the University of Siena where he also received his doctorate in Biotechnology. He later specialized in antibody therapeutics in clinical oncology at the Royal Postgraduate Medical School at the Hammersmith Hospital, London (1993-1995). As Director, he is responsible for developing the company's patent portfolio and is involved in the conclusion of all the major contractual agreements.
Co-founder and President of the Scientific Advisory Board of Philogen. He graduated in Chemistry at the Scuola Normale Superiore in Pisa and obtained his PhD in Chemistry from the ETH Zurich, under the supervision of Prof. Kurt Wüthrich, winner of the Nobel Prize for Chemistry, 2002. For his dissertation, he was awarded the Silver Medal of ETH. After a 5-year post-doctoral research position in the lab of Sir Gregory Winter at the Cambridge Centre of Protein Engineering in Cambridge, UK, he returned to the ETH Zurich in 1996 as Assistant Professor in Molecular Structure Biology. Since 1999, he has been a Professor in Biomacromolecules in the department of Chemistry and Applied Biosciences,(ETH).
He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe' Biotec Award 2000, of the Mangia d'Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer 2011 of the French Medicinal Chemistry Society and of the ERC Advanced Grant 2015.
Prof. Neri is author of more than 300 publications in international journals.
Sergio Dompé obtained three honorary degrees (pharmaceutical biotechnology from the University of Bologna in 1996, medical biotechnology from the University of L’Aquila in 2005 and pharmacy from the University of Urbino in 2010), as a result of his commitment to the pharmaceutical industry. In 1976, he started working for Dompé Farmaceutici S.p.A., founded by his father in 1940, and right from the start, brought many changes to the company’s strategy. He was among the first entrepreneurs in the industry to believe strongly in the opportunities offered by biotechnology for the development of new drugs. On the basis of this intuition, he established partnerships with global pharmaceutical companies to provide patients with new therapeutic benefits. Sergio Dompé holds the office of Chairman of Dompé Farmaceutici S.p.A., holding company of Dompé Group, which operates through three different companies, Dompé, Amgen Dompé and Biogen Dompé, and employs 800 persons globally and registered a turnover of 529.4 million Euros in 2010. From 1998 to 2004, Sergio Dompé was Chairman of Assobiotech for three consecutive terms in office. In June 2005 he was appointed President of Farmindustria, the Italian Pharmaceutical Companies’ Association and member of the Confindustria Council. Since January 2006, he has been Chairman of the Assessment Committee of the CNR (Italian Research Council). Since July 2007 he has been member of the Council of the Italian Institute of Technology foundation.
Roberto Marsella graduated in Business Economics at the Università Commerciale Luigi Bocconi in Milan, and later obtained an MBA from the Stern School of Business in New York. Extensive experience in investment banking & corporate finance in Italy and abroad gave way to his current position as Chairman of Tuctos, a corporate advisory firm. Roberto Marsella is also currently active in investment advising in small and medium businesses, as well as Vice Chairman of Finance for Philogen S.p.A.
Aged twenty-nine years old and a graduate in economics from Bocconi University of Milan, since 2012 Nathalie Dompé has been head of Corporate Social Responsibility activities for the Dompé Group, a biopharmaceutical company focused on the development of innovative therapeutic solutions for rare and orphan diseases.
Before this, she had accrued a variety of enriching personal experience: after graduating, she flew to London to study acting technique at the Saint Martins School of Arts, followed by volunteer work in an orphanage in Uganda. Even during secondary school, Nathalie had already volunteered at the Institute for the Sight Impaired of Milan, and it is precisely this desire to work for others that led her to choose to cover Corporate Social Responsibility in the Group.
In Dompé, Nathalie has chosen to work on projects capable of communicating to people the values that the Group holds or that may improve the knowledge and the level of awareness about relevant topics. It is an ambitious objective but one she has achieved thanks to the use of effective, innovative tools to spread awareness and create a tangible exchange with public opinion, paying particularly close attention to the younger generation.
She has been a member of the Board of Directors of Philogen since 2016.